company background image
KZR

Kezar Life Sciences NasdaqGS:KZR Stock Report

Last Price

US$6.04

Market Cap

US$364.9m

7D

14.2%

1Y

4.1%

Updated

24 Jun, 2022

Data

Company Financials +
KZR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

KZR Stock Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.

Kezar Life Sciences Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Kezar Life Sciences
Historical stock prices
Current Share PriceUS$6.04
52 Week HighUS$18.55
52 Week LowUS$4.31
Beta0.54
1 Month Change20.32%
3 Month Change-66.56%
1 Year Change4.14%
3 Year Change-21.66%
5 Year Changen/a
Change since IPO-65.97%

Recent News & Updates

Shareholder Returns

KZRUS BiotechsUS Market
7D14.2%10.3%6.6%
1Y4.1%-24.4%-18.5%

Return vs Industry: KZR exceeded the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: KZR exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is KZR's price volatile compared to industry and market?
KZR volatility
KZR Average Weekly Movement16.0%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: KZR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: KZR's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201556John Fowlerhttps://www.kezarlifesciences.com

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology.

Kezar Life Sciences Fundamentals Summary

How do Kezar Life Sciences's earnings and revenue compare to its market cap?
KZR fundamental statistics
Market CapUS$364.91m
Earnings (TTM)-US$57.66m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KZR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$57.66m
Earnings-US$57.66m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio4.2%

How did KZR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is KZR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KZR?

Other financial metrics that can be useful for relative valuation.

KZR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-2.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does KZR's PB Ratio compare to its peers?

KZR PB Ratio vs Peers
The above table shows the PB ratio for KZR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.5x

Price-To-Book vs Peers: KZR is expensive based on its Price-To-Book Ratio (1.6x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does KZR's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Book vs Industry: KZR is good value based on its Price-To-Book Ratio (1.6x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is KZR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KZR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KZR's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of KZR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KZR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KZR's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KZR's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Kezar Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-5.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KZR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KZR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KZR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KZR is forecast to have no revenue next year.

High Growth Revenue: KZR is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KZR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Kezar Life Sciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-32.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: KZR is currently unprofitable.

Growing Profit Margin: KZR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KZR is unprofitable, and losses have increased over the past 5 years at a rate of 32.1% per year.

Accelerating Growth: Unable to compare KZR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KZR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: KZR has a negative Return on Equity (-24.82%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Kezar Life Sciences's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: KZR's short term assets ($246.0M) exceed its short term liabilities ($7.0M).

Long Term Liabilities: KZR's short term assets ($246.0M) exceed its long term liabilities ($12.6M).


Debt to Equity History and Analysis

Debt Level: KZR has more cash than its total debt.

Reducing Debt: Insufficient data to determine if KZR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KZR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: KZR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 27.6% each year


Discover healthy companies

Dividend

What is Kezar Life Sciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate KZR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KZR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KZR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KZR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KZR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

John Fowler (48 yo)

7.25yrs

Tenure

US$5,645,417

Compensation

Mr. John Franklin Fowler serves as a Managing Director at Montebello Holdings, LLC. He is co-founder and Chief Executive Officer of Kezar Life Sciences since March 2015 and its Director since February 2015...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD5.65M) is above average for companies of similar size in the US market ($USD2.71M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: KZR's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: KZR's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.6%.


Top Shareholders

Company Information

Kezar Life Sciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Kezar Life Sciences, Inc.
  • Ticker: KZR
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$364.910m
  • Shares outstanding: 60.42m
  • Website: https://www.kezarlifesciences.com

Number of Employees


Location

  • Kezar Life Sciences, Inc.
  • 4000 Shoreline Court
  • Suite 300
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.